- Document Number:
20210008231
- Appl. No:
16/303599
- Application Filed:
May 19, 2017
- نبذة مختصرة :
The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung. The invention also provides Ro 32-3555 labeled with a radioisotope.
- Assignees:
The Trustees of Columbia University in the City of New York (New York, NY, US)
- Claim:
1. A method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung so as to image the subject's lung.
- Claim:
2. The method of claim 1, wherein the matrix metalloproteinase inhibitor is Ro 32-3555 or a modified form of CGS27023A.
- Claim:
3. The method of claim 2, wherein the radioisotope is I-123.
- Claim:
4. The method of claim 3, wherein the matrix metalloproteinase inhibitor is Ro 32-3555.
- Claim:
5. The method of claim 3, wherein the matrix metalloproteinase inhibitor is a modified form of CGS27023A.
- Claim:
6. The method of claim 5, wherein the modified form of CGS27023A has the structure: [chemical expression included] wherein X is OH and Y is H.
- Claim:
7. The method of claim 1, wherein the matrix metalloproteinase is labeled with a radioisotope has the structure: [chemical expression included] wherein X is OH and Y is I-123.
- Claim:
8. The method of claim 1, wherein the subject is, or is suspected of being, afflicted with a destructive lung disease.
- Claim:
9. (canceled)
- Claim:
10. The method of claim 8, wherein the destructive lung disease is chronic obstructive pulmonary disease (COPD), lymphangioleiomyomatosis (LAM), idiopathic pulmonary fibrosis (IPF), or acute lung injury (ALI).
- Claim:
11. The method of claim 8, wherein the destructive lung disease is emphysema.
- Claim:
12. The method of claim 1, wherein the imaging is single-photon emission computed tomography (SPECT) imaging.
- Claim:
13. The method of claim 1, wherein the contacting comprises administering to the subject an imageable amount of the matrix metalloproteinase inhibitor labeled with a radioisotope.
- Claim:
14. (canceled)
- Claim:
15. The method of claim 1, wherein the imaging is effected with a computer tomography (CT) scanner.
- Claim:
16-7. (canceled)
- Claim:
18. The method of claim 1, wherein the method further comprises determining the amount of matrix metalloproteinase (INSIP) expression or the amount of the label in the lung of the subject.
- Claim:
19-20. (canceled)
- Claim:
21. The method of claim 1, further comprising determining if the subject is afflicted with destructive lung disease.
- Claim:
22. The method of claim 1, further comprising determining the degree of lung destruction in the subject.
- Claim:
23. The method of claim 8, wherein the presence of MMP expression or the presence of the label in the subject's lung in an amount that is higher than a reference amount indicates that the subject is afflicted with a destructive lung disease,
- Claim:
24-26. (canceled)
- Claim:
27. The method of claim 8, wherein the amount of MMP expression or the amount of the label present in the subject's long determines the degree of lung destruction in the subject,
- Claim:
28. (canceled)
- Claim:
29. Ro 32-3555 labeled with a radioisotope.
- Claim:
30. The labeled Ro 32-3555 of claim 29 wherein the radioisotope is I-123.
- Current International Class:
61; 07
- الرقم المعرف:
edspap.20210008231
Processing Request
No Comments.